Steroid Glycosides Hyrcanoside and Deglucohyrcanoside: On Isolation, Structural Identification, and Anticancer Activity

Foods

Silvie Rimpelová¹  Tomáš Ruml¹  Jiří Bejček¹  Lucie Kuklíková¹  Bohumil Dolenský²  Michal Jurášek³  PavelB. Drašar³  Tomáš Zimmermann³  Petra Cihlářová³  Lubomír Opletal⁴  Eva Kmoníčková⁵  Marián Hajdůch⁶  Petr Džubák⁶  Soňa Gurská⁶ 

[1] Department Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic;Department of Analytical Chemistry, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic;Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Technická 5, 166 28 Prague, Czech Republic;Department of Pharmaceutical Botany, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic;Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic;Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital in Olomouc, Hněvotínská 976/3, 779 00 Olomouc, Czech Republic;

关键词: cardiac glycosides;    secondary plant metabolites;    natural product isolation;    hyrcanoside;    deglucohyrcanoside;    ouabain;   

DOI  :  10.3390/foods10010136

来源: DOAJ

【 摘 要 】

Cardiac glycosides (CGs) represent a group of sundry compounds of natural origin. Most CGs are potent inhibitors of Na⁺/K⁺-ATPase, and some are routinely utilized in the treatment of various cardiac conditions. Biological activities of other lesser known CGs have not been fully explored yet. Interestingly, the anticancer potential of some CGs was revealed and thereby, some of these compounds are now being evaluated for drug repositioning. However, high systemic toxicity and low cancer cell selectivity of the clinically used CGs have severely limited their utilization in cancer treatment so far. Therefore, in this study, we have focused on two poorly described CGs: hyrcanoside and deglucohyrcanoside. We elaborated on their isolation, structural identification, and cytotoxicity evaluation in a panel of cancerous and noncancerous cell lines, and on their potential to induce cell cycle arrest in the G2/M phase. The activity of hyrcanoside and deglucohyrcanoside was compared to three other CGs: ouabain, digitoxin, and cymarin. Furthermore, by in silico modeling, interaction of these CGs with Na⁺/K⁺-ATPase was also studied. Hopefully, these compounds could serve not only as a research tool for Na⁺/K⁺-ATPase inhibition, but also as novel cancer therapeutics.

【 授权许可】

Unknown